Project Grant HT94252411031
Award Date
11/1/24
Completion Date
10/31/26
Dollars Obligated
$311K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This $1,100,633 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports cancer research and translational science initiatives at the University of North Carolina at Chapel Hill (UNC-CH). Specifically, the award will fund innovative biomedical research projects focused on transforming healthcare for military service members and the broader public. Research areas may include disease prevention, diagnosis, treatment, and...
This federal Project Grant award of $509,979.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research initiatives at the University of North Carolina at Chapel Hill (UNC-CH) to develop potentiated chip variants as therapeutics to alleviate tau pathology and neurodegeneration. The award, with a performance period from July 1, 2025 to June 30, 2028, will fund innovative research projects aimed at transforming...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,511,536.00 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct a Testis Cancer Survivorship Study. The award period runs from July 1, 2024 to June 30, 2028. UNC-CH, through its Office of Sponsored Research, will execute this biomedical research initiative to transform healthcare for military service members and...
This $544,250 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of North Carolina at Chapel Hill to develop combination therapies to overcome chemoresistance in Ewing sarcoma. The research project, which has a performance period from August 15, 2024 to August 14, 2027, aims to advance innovative therapeutic approaches to improve outcomes for this rare and aggressive form of cancer. As a...
The University of North Carolina at Chapel Hill will receive $3,863,892 under a four-year Project Grant from the Defense Health Agency to integrate molecular pathology, radiology, and genetics to improve breast cancer risk prediction. The grant, awarded on September 15, 2023 under the Military Medical Research and Development program, will support the university's efforts to transform military and public health care by investigating medical solutions for the battlefield and innovative research...
This $489,065 Project Grant was awarded by the Defense Health Agency on July 1, 2025 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award funds research at the University of North Carolina at Chapel Hill (UNC-CH) to develop "Potentiated Chip Variants as Therapeutics to Alleviate Tau Pathology and Neurodegeneration". The research aims to explore innovative approaches to preventing, diagnosing, and treating neurodegenerative conditions,...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,541,280.00 to the University of North Carolina at Chapel Hill to support the "The Breast Cancer Cellular Atlas" research project. This multi-year project, running from March 2025 through February 2029, will conduct innovative biomedical research to advance understanding and treatment of breast cancer. The funding will enable UNC-Chapel...
The University of North Carolina at Chapel Hill will use a $1,265,834 project grant from the Department of the Army Medical Command to support research titled "GD2 CART FOR LUNG CANCER" under the Military Medical Research and Development program (CFDA 12.420). The three-year award beginning September 30, 2022 will fund the development of chimeric antigen receptor T-cell (CART) therapies targeting the GD2 antigen for treatment of lung cancer. The Military Medical Research and...
This $602,550 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) supports adoptive cellular therapy research for pancreatic cancer. The awardee, the University of Nebraska Medical Center (UNMC), will conduct innovative biomedical research to develop novel therapeutic approaches, perform clinical trials, and provide technical expertise in this critical medical field. As a prominent academic research...
The Defense Health Agency awarded a $602,814 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from November 1, 2024 to October 31, 2027, supports research to investigate "Targeting Extracellular Nucleoside Metabolism as a Strategy to Potentiate the Effects of Immunotherapy in Pancreatic Ductal Adenocarcinoma." The project aims to explore innovative approaches...